ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 249 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $416,898 | -13.3% | 76,495 | +6.8% | 0.10% | -12.6% |
| Q2 2023 | $480,604 | -24.0% | 71,625 | 0.0% | 0.12% | -22.2% |
| Q1 2023 | $632,449 | +44.7% | 71,625 | +25.2% | 0.15% | +44.3% |
| Q4 2022 | $437,046 | +7.4% | 57,205 | 0.0% | 0.11% | +9.3% |
| Q3 2022 | $407,000 | -8.9% | 57,205 | +3.5% | 0.10% | -7.6% |
| Q2 2022 | $447,000 | +49.0% | 55,265 | +155.8% | 0.10% | -2.8% |
| Q1 2022 | $300,000 | -67.1% | 21,605 | -33.5% | 0.11% | -44.0% |
| Q4 2021 | $911,000 | +45.5% | 32,475 | +76.3% | 0.19% | +2.7% |
| Q3 2021 | $626,000 | -46.7% | 18,425 | -35.9% | 0.19% | -44.4% |
| Q2 2021 | $1,175,000 | +73.0% | 28,762 | +70.6% | 0.34% | +47.0% |
| Q1 2021 | $679,000 | -36.1% | 16,862 | -6.2% | 0.23% | -32.7% |
| Q4 2020 | $1,062,000 | -11.4% | 17,972 | -27.1% | 0.34% | -5.8% |
| Q3 2020 | $1,198,000 | +91.7% | 24,642 | +90.9% | 0.36% | +103.9% |
| Q2 2020 | $625,000 | – | 12,910 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |